TITLE

Fast Forward®Ô Fast-tracking new therapies

PUB. DATE
December 2011
SOURCE
Momentum (19403410);Winter2011/2012, Vol. 5 Issue 1, p58
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the research collaborations and partnerships of Fast Forward, which is on the development of new therapies for people with multiple sclerosis (MS). It notes that Fast Forward and the Juvenile Diabetes Research Foundation have partnered with Axxam SpA, a subsidiary of Bayer AG, in identifying compounds for use in treating MS and diabetes. Fast Forward is also seeking to create a collaborative environment in MS research among scientists, clinicians, and industry.
ACCESSION #
86447776

 

Related Articles

  • In the news and on our website.  // Momentum (19403410);Fall2012, Vol. 5 Issue 4, p63 

    The article offers news briefs related to multiple sclerosis studies in the U.S. A study reveals the advantage of a six-week balance and eye movement-focused exercise which can improve balance and minimize fatigue. A study unveils that hot weather conditions can worsen the ability of people with...

  • In the news and on our website.  // Momentum (19403410);Winter2012/2013, Vol. 6 Issue 1, p60 

    The article offers news briefs related to diagnosis and treatment of multiple sclerosis (MS) in the U.S. Pharmaceutical firms Merck Serono SA and Fast Forward LLC have partnered to support biotechnology company Axxam SpA in the prevention of disability in MS. Pharmaceutical firm Novartis AG has...

  • International MS Falls Prevention Research Network. Sosnoff, Jacob J.; Finlayson, Marcia // International Journal of MS Care;2014, Vol. 16 Issue 4, p161 

    An introduction is presented in which the editors discuss various reports within the issue on topics including postural control of older adults with multiple sclerosis (MS), falls-prevention in people with MS, and measurement tools used for an MS falls-prevention intervention.

  • Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Constantinescu, Cris // Current Medical Literature: Multiple Sclerosis;2014, Vol. 6 Issue 2, p59 

    A review is offered for the article "Delta-9-tetrahydrocannabinol/cannabidiol (Sativex): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis" by Y. Y. Syed and colleagues, published in the 2014 issue of the journal "Drugs."

  • Cannabinoids control spasticity and tremor in a multiple sclerosis model. Baker, David; Pryce, Gareth // Nature;3/2/2000, Vol. 404 Issue 6773, p84 

    Reveals that cannabinoids, such as tetrahydrocannabinol and methanandamide, control spasticity and tremor in a multiple sclerosis model. Chronic relapsing experimental allergic encephalomyelitis (CRAEA); CRAEA induction to myelin antigens; Perceived benefits of cannabis and alternative medicine.

  • The economic impact of multiple sclerosis in Australia in 2010. Magyari, Melinda // Current Medical Literature: Multiple Sclerosis;2013, Vol. 5 Issue 4, p121 

    The article presents a review of the study regarding the economic effect of multiple sclerosis (MS) in Australia in 2010. It provides details of the survey take in 2003 and 2007 to determine the direct costs involved in the treatment of MS. It outlines the findings of the study and concludes the...

  • Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Agashivala, Neetu; Wu, Ning; Abouzaid, Safiya; Wu, You; Kim, Edward; Boulanger, Luke; Brandes, David W. // BMC Neurology;2013, Vol. 13 Issue 1, p1 

    Background: Adherence to disease-modifying therapies (DMTs) results in the reduction of the number and severity of relapses and delays the progression of multiple sclerosis (MS). Patients with lower adherence rates experience more inpatient visits and higher MS-related medical costs. Fingolimod,...

  • Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned to Teva's COPAXONE(r).  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article provides information on an open label survey study conducted by Teva Pharmaceutical Industries Ltd. to evaluate spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to Teva's COPAXONE(®) from interferon-beta treatment. The results from the...

  • Piecing the puzzle together. Weick, Rachel // Grand Rapids Business Journal;7/27/2015, Vol. 33 Issue 30, p1 

    The article offers information on medical research project Agent Z which aims to cure the autoimmune diseases multiple sclerosis.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics